Natamycin - instructions for use, dose, side effects, contraindications

Binding to sterols of the cell membrane of fungi, mainly with ergosterol, with an increase in membrane permeability: the formation of pores through which small molecules leak. Fungal cell damage due to free radical oxidation (in vitro). Pharmacological effects: antifungal, fungistatic, fungicidal. Spectrum of antimicrobial activity: Candida albicans, Trichophyton spp., Microsporum spp., Epidermophyton spp., Torulopsis spp., Rhodoturola spp., Aspergillus spp., Penicillium spp., Fusarium solani and etc.

Not effective against bacteria, rickettsia and viruses.

Pharmacokinetics:

Absorption from the gastrointestinal tract, from the surface of the skin and mucous membranes is negligible. Tablets for oral administration do not have a systemic effect.

Indications:

Fungal diseases of the skin and mucous membranes, caused by natamycin-sensitive pathogens,including acute pseudomembranous and acute atrophic candidiasis against cachexia and immune deficiency, as well as after therapy with antibiotics, corticosteroids and cytostatics; candidiasis of skin and nails, intestinal candidiasis; vaginitis, vulvitis, vulvovaginitis, balanoposthitis caused mainly by fungi Candida; dermatomycosis; otomycosis, external otitis (including primarily caused by fungi or complicated by candidiasis); as an additional therapy in the treatment of dermatomycosis with griseofulvin.

ICD-10

I.B35-B49.B37.9 Candidiasis, unspecified

I.B35-B49.B37.8 Candidiasis of other localizations

I.B35-B49.B37.4 Candidiasis of other urogenital localizations

I.B35-B49.B37.3 Candidiasis of the vulva and vagina (N77.1 *)

I.B35-B49.B37.2 Candidiasis of skin and nails

I.B35-B49.B37.0 Candidiasis stomatitis

I.B35-B49.B37 Candidiasis

I.B20-B24.B20.4 The disease caused by HIV, with manifestations of candidiasis

VIII.H60-H62.H62.2 * External otitis with fungal infections

II.C81-C96.C84.0 Mushroom mycosis

I.B35-B49.B49 Mycosis, unspecified

I.B35-B49.B48.8 Other specified mycoses

I.B35-B49.B48 Other mycoses, not elsewhere classified

I.B35-B49.B36.9 Superficial mycosis, unspecified

I.B35-B49.B36.8 Other specified surface fungal infections

I.B35-B49.B36 Other superficial fungal infections

I.B35-B49.B35.4 Mycosis of the trunk

I.B35-B49.B35.3 Mycosis of the feet

I.B35-B49.B35.2 Mycosis brushes

I.B35-B49.B35.1 Mycosis of nails

I.B35-B49.B35.0 Mycosis of the beard and head

I.B35-B49 Mycosis

Contraindications:

Hypersensitivity, skin tuberculosis. Children under 18 years of age, pregnancy.

Carefully:

Elderly age, renal and hepatic insufficiency, breast-feeding.

Pregnancy and lactation:

The category of FDA recommendations is not defined.

Contraindicated in pregnancy.

Dosing and Administration:

When administered orally, a single dose is 100 mg. Multiplicity of admission for adults - 4 times a day, for children - 2 times a day.

Outer and topically applied 1 time or several times a day.

Intravaginal - 1 time per day at night for 3-6 days.

The duration of the course of treatment is set individually. After the disappearance of the symptoms of the disease is recommended to continue treatment a few more days.

Side effects:

When ingestion - nausea, vomiting, diarrhea; with local use - slight irritation and burning sensation in the place of application.

Overdose:

Not described.

Interaction:

Antifungal derivatives of azoles - antagonism.

Flucytosine is a synergistic action.

Special instructions:

In the case of a chronic or recurrent infection, local treatment can be supplemented with a systemic application.

During menstruation natamycin do not use intravaginally.

With intravaginal application, there is no need to exclude sexual contact. However, it is recommended to conduct a survey of sexual partners and, in case of detection of candidiasis defeat, to conduct a course of treatment with natamycin. Also, during the period of treatment, barrier means of contraception should be used.

Natamycin can be administered neonately with caution.

Instructions

Natamycin (Natamycinum)